MBOT News & Events

Microbot Medical announced that it has successfully executed its limited market release and will commence the full market release of its LIBERTY endovascular robotic system in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks. The company stated it is showcasing the system at the Society of Interventional Radiology Annual Scientific Meeting to further educate physicians and accelerate market adoption. "We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference," said Harel Gadot, chairman and CEO. "It's exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network."

Microbot Medical announced that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional. Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquartered in Hingham, MA. This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned. The Company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through its U.S.-based third-party logistics partner to meet anticipated demand.